Health Care [ 12/12 ] | Biotechnology [ 62/74 ]
NASDAQ | Common Stock
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States.
The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.
Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock.
The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter.
It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas.
Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Dec 8, 23 | 1.09 Decreased by -2.68% | 1.09 |
| Aug 8, 23 | 1.18 Decreased by -24.36% | 1.05 Increased by +12.38% |
| May 9, 23 | 1.26 Decreased by -68.81% | 1.05 Increased by +20.00% |
| Mar 13, 23 | 1.10 Increased by +29.41% | 0.83 Increased by +32.53% |
| Nov 7, 22 | 1.12 Increased by +100.00% | 0.91 Increased by +23.08% |
| Aug 9, 22 | 1.56 Increased by +67.74% | 3.36 Decreased by -53.57% |
| May 9, 22 | 4.04 Increased by +1.58 K% | 3.88 Increased by +4.12% |
| Mar 7, 22 | 0.85 Decreased by -11.46% | 0.94 Decreased by -9.57% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 23 | 64.65 M Decreased by -12.80% | 5.16 M Increased by +154.65% | Increased by +7.99% Increased by +162.67% |
| Mar 31, 23 | 66.31 M Decreased by -42.78% | 5.75 M Decreased by -86.95% | Increased by +8.67% Decreased by -77.19% |
| Dec 31, 22 | 60.70 M Increased by +43.43% | 8.16 M Increased by +231.78% | Increased by +13.45% Increased by +191.88% |
| Sep 30, 22 | 65.90 M Increased by +65.36% | -3.51 M Increased by +37.51% | Decreased by -5.33% Increased by +62.21% |
| Jun 30, 22 | 74.14 M Increased by +54.05% | -9.45 M Decreased by -361.63% | Decreased by -12.75% Decreased by -269.83% |
| Mar 31, 22 | 115.87 M Increased by +180.91% | 44.06 M Increased by +10.57 K% | Increased by +38.02% Increased by +3.83 K% |
| Dec 31, 21 | 42.32 M Decreased by -15.22% | -6.20 M Decreased by -176.90% | Decreased by -14.64% Decreased by -190.71% |
| Sep 30, 21 | 39.85 M Decreased by -20.18% | -5.62 M Decreased by -179.64% | Decreased by -14.11% Decreased by -199.78% |